The ACCORD Study Group. NEJM 2010; Epub March 14

Slides:

Advertisements

Similar presentations

The INSIGHT study - Reliable blood pressure control and additional benefits for hypertensive patients Anthony M Heagerty Department of Medicine Manchester.

Advertisements

CHARM Program: 3 Component trials comparing candesartan with placebo.

BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.

Glynn RJ, et al. N Engl J Med 2009 Mar 29 [Epub ahead of print]

EFFECTIVENESS OF A MEDICAL EDUCATION INTERVENTION TO TREAT HYPERTENSION IN PRIMARY CARE Authors Institutions Authors: Silvia Martínez-Valverde MSc 1, Hortensia.

Flow Diagram of the Main HOPE Trial and the HOPE-TOO Trial Extension The HOPE and HOPE-TOO Trial Investigators JAMA. 2005;293:

Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.

Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:

The ACTIVE Investigators. N Engl J Med 2009 Apr 3 [Epub]

Kaplan-Meier analysis of time to recurrent congestive heart failure or death in patients prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory.

Shalev V, et al. Arch Intern Med 2009; 169:

Trial profile Prakash Deedwania, et al. Lancet 2006; 368:

Trial profile The FIELD study investigators, Lancet Published online November 14, 2005.

Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.

Baseline Characteristics of the Patients* - Part I The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]

Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:

Date of download: 5/27/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effect of Dietary Protein Content on Weight Gain,

Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of a Fixed-Dose Combination Strategy on Adherence.

Date of download: 5/29/2016 From: The Effect of a Lower Target Blood Pressure on the Progression of Kidney Disease: Long-Term Follow- up of the Modification.

Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Safety and Efficacy of Low Blood Pressures Among.

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Smoking Is Associated With Adverse Clinical Outcomes.

Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Hypertension J Am Coll Cardiol. 2006;48(8):

Date of download: 7/5/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Oral Iron Supplementation After Blood Donation: A.

Summary of “A randomized trial of standard versus intensive blood-pressure control” The SPRINT Research Group, NEJM, DOI: /NEJMoa Downloaded.

Sample Journal Club Your Name Here.

The SPRINT Research Group

Early Surgery versus Conventional Treatment for Infective Endocarditis

Copyright © 2007 American Medical Association. All rights reserved.

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

Trial profile SAS denotes the Simvastatin in Aortic Stenosis Study

Career choice for Chinese medical graduate: Safety Physician

Neal B, et al. Diabetes Care 2015;38:403–411

Tetsuro Tsujimoto, Hiroshi Kajio International Journal of Cardiology

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

Teaching Tool: Blood Pressure Classification

Systolic Blood Pressure Intervention Trial (SPRINT)

Monitoring rare events during an ongoing clinical trial

Clinical Application of New CV Outcomes Data

TNT Study: Baseline Characteristics of the Patients

Trial profile John A Dormandy et al. Lancet 2005;366:

Fellström BC, et al. N Engl J Med 2009;360:1455-7

Aspirin and Cardioprevention in 2018

BAT for HFrEF Trial design: Patients with chronic systolic HF were randomized in a 1:1 fashion to either baroreceptor activation therapy (BAT) or control.

Tetsuro Tsujimoto, Hiroshi Kajio International Journal of Cardiology

Figure 1 Study flow diagram and definition of clinical response

Daan Kromhout, et al. NEJM epub August 29, 2010

Enrollment and Outcomes

Long-term study of mycophenolate mofetil treatment in IgA nephropathy

Trial profile GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

Trial profile GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

Berger JS, et al. JAMA 2009;301:

Characteristics of the Patients at Baseline*

Flow of Patients Through Trial

Baseline Characteristics of the Study Participants

Baseline Characteristics, Blood Pressures, and Laboratory Values

Jeffrey S. Berger, et al. Circ Cardiovasc Qual Outcomes 2009;2:78-87

Patient Disposition James A. de Lemos et al. JAMA 2004; 292:

Participation in Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Hisao Ogawa et al. JAMA 2008;300:

Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Relative Risk of Onset of Cancer from the Cholesterol Treatment Trialists’ (CTT) Meta-Analysis of Statin Trials, According to Year of Onset Risk ratios.

RECORD Study: Enrollment and Outcomes

Volume 73, Issue 8, Pages (April 2008)

DRCR Retina Network Treatment for Center-Involved DME in Eyes with Good Visual Acuity (Protocol V)

Baseline Characteristics of the Patients - Part I

Enrollment and Outcomes

The ACCORD Study Group. NEJM 2010; Epub March 14

Volume 60, Issue 3, Pages (September 2001)

Volume 75, Issue 1, Pages (January 2009)

The Kaplan-Meier curves display the time to event for the primary outcome (A) and total mortality (B) during follow-up from randomization until the end.

Presentation transcript:

The ACCORD Study Group. NEJM 2010; Epub March 14

Characteristics of the Participants at Baseline* - Part I The ACCORD Study Group. NEJM 2010; Epub March 14

Characteristics of the Participants at Baseline* - Part II The ACCORD Study Group. NEJM 2010; Epub March 14

Mean Systolic Blood-Pressure Levels at Each Study Visit I bars indicate 95% confidence intervals The ACCORD Study Group. NEJM 2010; Epub March 14

Serious Adverse Events and Clinical Measures after Randomization* The ACCORD Study Group. NEJM 2010; Epub March 14

Primary and Secondary Outcomes The ACCORD Study Group. NEJM 2010; Epub March 14

Kaplan–Meier Analyses of Selected Outcomes Shown are the proportions of patients with events for the primary composite outcome (Panel A) and for the individual components of the primary outcome (Panels B, C, and D). The insets show close-up versions of the graphs in each panel. The ACCORD Study Group. NEJM 2010; Epub March 14